FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

堆栈库

Cellular Youth Protocol

Anti-Aging & Longevitybeginner
35
Share
肽类

2

平均每日mcg

5,200

级别

beginner

添加时间

May 16, 2026

概述

The Cellular Youth Protocol is a beginner-friendly longevity stack that targets aging at its most fundamental level—cellular DNA integrity and tissue repair signaling. By combining Epithalon with GHK-Cu, this protocol addresses two core mechanisms of biological aging: telomere shortening and extracellular matrix degradation. Epithalon (Epitalon), dosed at 5000mcg daily, is a synthetic tetrapeptide based on the natural pineal gland peptide Epithalamin. Its primary mechanism involves activating telomerase, the enzyme responsible for maintaining telomere length on chromosomes. Telomere attrition is one of the hallmarks of aging identified in modern geroscience research. Studies by Professor Vladimir Khavinson demonstrated that Epithalon treatment increased telomerase activity in human somatic cells, effectively slowing the cellular clock. Beyond telomere maintenance, Epithalon supports melatonin production, antioxidant enzyme regulation, and normalized circadian signaling. GHK-Cu (copper peptide) at 200mcg daily is a naturally occurring tripeptide that declines significantly with age. It functions as a powerful tissue remodeling signal, stimulating collagen synthesis, promoting wound healing, reducing inflammation, and activating DNA repair genes. Research has identified over 4,000 genes modulated by GHK-Cu, many involved in antioxidant defense, stem cell activity, and suppression of fibrous tissue formation. Users commonly report improvements in skin elasticity, hair quality, and recovery from minor injuries. The synergy between these two peptides is elegant: Epithalon preserves cellular replicative capacity from within while GHK-Cu optimizes the extracellular environment and repair signaling. Together they address aging from both the genomic and tissue-structure levels. Protocol Notes: Both peptides are administered subcutaneously. Epithalon is typically cycled in 10-20 day courses with breaks between cycles. GHK-Cu can be run continuously. This stack is ideal for individuals over 35 seeking proactive longevity support, improved skin and tissue quality, and foundational anti-aging benefits without complex dosing schedules.

给药方案

5,000 mcg

每剂

200 mcg

每剂

目标与证据

证据等级:community

Comments

Sign in to join the discussion

免责声明: 此堆栈由社区提交,仅供研究用途。Peptide Contacts不对提交的堆栈的安全性或有效性进行验证。使用任何肽类协议前,请务必咨询合格的医疗专业人员。